Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 381

1.

Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.

Beuselinck B, Vano YA, Oudard S, Wolter P, De Smet R, Depoorter L, Teghom C, Karadimou A, Zucman-Rossi J, Debruyne PR, Van Poppel H, Joniau S, Lerut E, Strijbos M, Dumez H, Paridaens R, Van Calster B, Schöffski P.

BJU Int. 2014 Jul;114(1):81-9. doi: 10.1111/bju.12494. Epub 2014 Jan 15.

2.
3.

VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.

Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, van Poppel H, Paridaens R, Schöffski P, Méjean A, Verkarre V, Lerut E, Joly F, Lebret T, Gravis G, Deplanque G, Descazeaud A, Leclercq NR, Molinié V, Patard JJ, Teghom C, Elaidi R, Zucman-Rossi J, Oudard S.

Acta Oncol. 2014 Jan;53(1):103-12. doi: 10.3109/0284186X.2013.770600. Epub 2013 Feb 20.

PMID:
23421954
4.

Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.

Yuasa T, Tsuchiya N, Urakami S, Horikawa Y, Narita S, Inoue T, Saito M, Yamamoto S, Yonese J, Fukui I, Nakano K, Takahashi S, Hatake K, Habuchi T.

BJU Int. 2012 May;109(9):1349-54. doi: 10.1111/j.1464-410X.2011.10534.x. Epub 2011 Aug 25.

5.

Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer.

Kawai Y, Osawa T, Kobayashi K, Inoue R, Yamamoto Y, Matsumoto H, Nagao K, Hara T, Sakano S, Nagamori S, Matsuyama H.

Asian Pac J Cancer Prev. 2015;16(14):5687-90.

6.

Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib.

Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Hammers H, Eisenberger MA, Sinibaldi V, Pili R, Hayat H, Kovel S, Sella A, Boursi B, Weitzen R, Mermershtain W, Rouvinov K, Berger R, Carducci MA.

Oncologist. 2014 Jan;19(1):51-60. doi: 10.1634/theoncologist.2012-0335. Epub 2013 Dec 5.

7.

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.

Donskov F, Michaelson MD, Puzanov I, Davis MP, Bjarnason GA, Motzer RJ, Goldstein D, Lin X, Cohen DP, Wiltshire R, Rini BI.

Br J Cancer. 2015 Dec 1;113(11):1571-80. doi: 10.1038/bjc.2015.368. Epub 2015 Oct 22.

8.

Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.

Iacovelli R, Lanoy E, Albiges L, Escudier B.

BJU Int. 2012 Dec;110(11):1747-53. doi: 10.1111/j.1464-410X.2012.11518.x. Epub 2012 Oct 26.

9.

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.

Harmon CS, DePrimo SE, Figlin RA, Hudes GR, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Williams JA, Eisen T, Motzer RJ.

Cancer Chemother Pharmacol. 2014 Jan;73(1):151-61. doi: 10.1007/s00280-013-2333-4. Epub 2013 Nov 13.

10.

Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.

Izzedine H, Derosa L, Le Teuff G, Albiges L, Escudier B.

Ann Oncol. 2015 Jun;26(6):1128-33. doi: 10.1093/annonc/mdv147. Epub 2015 Mar 20.

11.

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration.

Bamias A, Tzannis K, Beuselinck B, Oudard S, Escudier B, Diosynopoulos D, Papazisis K, Lang H, Wolter P, de Guillebon E, Stravodimos K, Chrisofos M, Fountzilas G, Elaidi RT, Dimopoulos MA, Bamia C.

Br J Cancer. 2013 Jul 23;109(2):332-41. doi: 10.1038/bjc.2013.341. Epub 2013 Jun 27.

12.

Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.

Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA.

Eur J Cancer. 2012 May;48(7):1031-7. doi: 10.1016/j.ejca.2012.02.050. Epub 2012 Mar 10.

PMID:
22409947
13.

Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.

Thian Y, Gutzeit A, Koh DM, Fisher R, Lote H, Larkin J, Sohaib A.

Radiology. 2014 Nov;273(2):452-61. doi: 10.1148/radiol.14132702. Epub 2014 May 26.

PMID:
24869795
14.

The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.

Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, Carducci MA.

Eur J Cancer. 2012 Jan;48(2):202-8. doi: 10.1016/j.ejca.2011.09.001. Epub 2011 Oct 19.

15.
16.

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma.

Motzer RJ, Escudier B, Bukowski R, Rini BI, Hutson TE, Barrios CH, Lin X, Fly K, Matczak E, Gore ME.

Br J Cancer. 2013 Jun 25;108(12):2470-7. doi: 10.1038/bjc.2013.236. Epub 2013 May 21.

17.

Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.

Livne-Segev D, Gottfried M, Maimon N, Peer A, Neumann A, Hayat H, Kovel S, Sella A, Mermershtain W, Rouvinov K, Boursi B, Weitzen R, Berger R, Keizman D.

Isr Med Assoc J. 2014 Jun;16(6):347-51.

18.

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, Motzer RJ.

J Natl Cancer Inst. 2011 May 4;103(9):763-73. doi: 10.1093/jnci/djr128. Epub 2011 Apr 28.

19.

C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib.

Fujita T, Iwamura M, Ishii D, Tabata K, Matsumoto K, Yoshida K, Baba S.

Int J Urol. 2012 Oct;19(10):908-13. doi: 10.1111/j.1442-2042.2012.03071.x. Epub 2012 Jun 6.

20.

Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.

Xie M, He CS, Huang JK, Lin QZ.

Eur J Cancer. 2015 Mar;51(5):595-603. doi: 10.1016/j.ejca.2015.01.005. Epub 2015 Jan 21.

PMID:
25618828
Items per page

Supplemental Content

Write to the Help Desk